New aliphatic acid amides from Streptomyces maoxianensis sp. nov.
The Journal of Antibiotics advance online publication, July 27 2016. doi:10.1038/ja.2016.90
Authors: Jin-Meng Li, Kai Yan, Hui Zhang, Huan Qi, Ji Zhang, Wen-Sheng Xiang, Ji-Dong Wang & Xiang-Jing Wang
In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates
The Journal of Antibiotics advance online publication, July 27 2016. doi:10.1038/ja.2016.93
Authors: Yongbo Zhang, Peizhen Li, Yuhan Yin, Fuqiang Li & Qinghua Zhang
Identification of a prodigiosin cyclization gene in the roseophilin producer and production of a new cyclized prodigiosin in a heterologous host
The Journal of Antibiotics advance online publication, July 27 2016. doi:10.1038/ja.2016.94
Authors: Shoko Kimata, Masumi Izawa, Takashi Kawasaki & Yoichi Hayakawa
Versicones E–H and arugosin K produced by the mangrove-derived fungus Aspergillus versicolor HDN11-84
The Journal of Antibiotics advance online publication, July 27 2016. doi:10.1038/ja.2016.95
Authors: Feng Li, Wenqiang Guo, Qian Che, Tianjiao Zhu, Qianqun Gu & Dehai Li
In this Leading article, we summarize current knowledge of the occurrence of the first and so far only transferable colistin resistance gene, mcr-1. Its location on a conjugative plasmid is likely to have driven its spread into a range of enteric bacteria in humans and animals. Screening studies have identified mcr-1 in five of the seven continents and retrospective studies in China have identified this gene in Escherichia coli originally isolated in the 1980s, while the first European isolate dates back to 2005. Based on the widespread use of colistin in pigs and poultry in several countries and the higher number of mcr-1-carrying isolates of animal origin than of human origin, it is tempting to assume that this resistance may have emerged in the animal sector. Whatever its origin, interventions to reduce its further spread will require an integrated global one-health approach, comprising robust antibiotic stewardship to reduce unnecessary colistin use, improved infection prevention, and control and surveillance of colistin usage and resistance in both veterinary and human medicine.
Despite the recognized problem of antibiotic multidrug resistance, very few antibacterial agents with new mechanisms of action are under development. Bacteriophage therapy could offer one alternative strategy to mitigate this challenge. Although widely used throughout the 20th century in Eastern Europe and the former Soviet Union, this potential therapy has not yet been investigated according to rigorous scientific standards. This paper reports on a multistakeholder meeting held at the EMA, which outlined the existing regulatory framework to which such therapy should adhere and reviewed the current obstacles and shortcomings in scientific development for bacteriophage therapy.
